Adipose tissue-derived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation. Cytotherapy. 2010 Aug 26; Authors: Technau A, Froelich K, Hagen R, Kleinsasser N Abstract Background aims. The chondrogenic differentiation potential of mesenchymal stromal cells (MSC), as well as their immunosuppressive properties, have been studied extensively. So far, only a few studies have addressed the question of whether MSC still retain their immunosuppressive qualities after transdifferentiation. In particular, the expression of immunogenic markers, such as human leukocyte antigen (HLA)-DR, after differentiation has never been investigated. Methods. Chondrogenic transdifferentiation was induced in human adipose tissue-derived stem cell (ADSC) pellet cultures derived from 10 different patients, using 10 ng/mL transforming growth factor (TGF)-beta3. Samples were harvested over a time-course of 28 days and analyzed by immunohistochemistry and reverse transcription (RT)-polymerase chain reaction (PCR). The cytokine levels in the supernatants of the samples were measured semi-quantitatively by dot-blots and quantitatively by enzyme-linked immunosorbant assays (ELISA). Results. Undifferentiated ADSC were negative for chondrogenic markers, as well as HLA-ABC and HLA-DR epitopes in immunofluorescence. In contrast, TGF-beta3-induced pellet cultures showed both expression of chondrogenic differentiation markers, such as transcription factor 9 (Sox 9), collagen type IIa and aggrecan, and an up-regulation of HLA-DR, beginning at day 7 after induction. Interferon-gamma (INF-gamma) is known to up-regulate HLA-DR. Therefore we measured INF-gamma levels in the supernatants of TGF-beta3-induced pellets and, indeed, INF-gamma was up-regulated during chondrogenesis in ADSC pellet cultures. However, both undifferentiated and TGF-beta3-induced ADSC also showed expression of immunosuppressive HLA-G and interleukin (IL)-10 up-regulation. Conclusions. These results suggest that the immunogenicity of adult stem cell-derived tissue should be tested in animal models before clinical trials for allogeneic engineered tissue are considered. PMID: 20795757 [PubMed - as supplied by publisher] |
No comments:
Post a Comment